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Decreased expression of peroxisome proliferator activated receptor-γ (PPARγ) and high levels of the proinflammatory enzyme
cyclooxygenase-2 (COX-2) have been observed in many tumor types. Both reduced (PPARγ) expression and elevated COX-2
within the tumor are associated with poor prognosis in lung cancer patients, and recent work has indicated that these signaling
pathways may be interrelated. Synthetic (PPARγ) agonists such as the thiazolidinedione (TZD) class of anti-diabetic drugs can
decrease COX-2 levels, inhibit growth of non-small-cell lung cancer (NSCLC) cells in vitro, and block tumor progression in
xenograft models. TZDs alter the expression of COX-2 and consequent production of the protumorigenic inflammatory molecule
prostaglandin E2 (PGE2) through both (PPARγ) dependent and independent mechanisms. Certain TZDs also reduce expression of
PGE2 receptors or upregulate the PGE2 catabolic enzyme 15-prostaglandin dehydrogenase. As several COX-2 enzymatic products
have antitumor properties and specific COX-2 inhibition has been associated with increased risk of adverse cardiac events,
directly reducing the effects or concentration of PGE2 may provide a more safe and effective strategy for lung cancer treatment.
Understanding the mechanisms underlying these effects may be helpful for designing anticancer therapies. This article summarizes
recent research on the relationship between (PPARγ), TZDs, and the COX-2/PGE2 pathways in lung cancer.
Copyright © 2008 Saswati Hazra et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Despite the many advances made in diagnostic and treatment
strategies, lung cancer remains the leading cause of cancer-
related mortality in the United States and is responsible for
more deaths than prostate, colon, and breast cancers com-
bined [1]. Investigating the molecular mechanisms underly-
ing the pathogenesis of lung cancer provides opportunities
to develop innovative therapies that may reduce suffering
due to this devastating disease. Decreased expression of per-
oxisome proliferator activated receptor (PPARγ) originally
identified as a regulator of glucose metabolism and adipocyte
differentiation [2] has been associated with poor prognosis
in lung cancer patients [3]. PPARγ affects inflammatory
gene expression, cell division, apoptosis, invasion, release of
proangiogenic cytokines, and differentiation in many cancer
types including lung cancer [4–8]. These properties have
prompted extensive research on PPARγ in cancer treatment
and prevention. Members of the thiazolidinedione (TZD)
class of PPARγ agonists are currently approved for treatment
of diabetes, and elicit many of the antitumor properties of
PPARγ activation through both PPARγ dependent and inde-
pendent pathways [9–14]. Several studies have demonstrated
elevated constitutive expression of the inducible proinflam-
matory enzyme, cyclooxygenase-2 (COX-2) in human lung
cancer [15–19]. Mounting evidence from investigations into
the molecular effects of COX-2 over-expression in lung
tumor cells indicates that this enzyme has a multifaceted
role in conferring the malignant and metastatic phenotypes.
The COX-2 enzymatic product prostaglandin E2 (PGE2) has
been implicated in apoptosis resistance [20–22], angiogene-
sis [23, 24], decreased host immunity [25, 26], and enhanced
invasion and metastasis [27–29]. This review summarizes
investigations in the relationship between PPARγ, its ligands,
and COX-2 and PGE2 in lung cancer.
The PPAR family consists of three isoforms: PPARα,
PPARγ, and PPARδ, each encoded by different genes.
PPARs are members of the nuclear hormone class of
receptors and are involved in energy metabolism through
transcriptional regulation of specific gene sets. Observations
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regarding high PPARγ expression in adipose tissue in
combination with its role in lipid and glucose homeostasis
led to the development of the TZD class of PPARγ ago-
nists, including troglitazone, ciglitazone, rosiglitazone, and
pioglitazone as antidiabetic and insulin-sensitizing drugs.
Rosiglitazone and pioglitazone are currently approved for
treatment of type 2 diabetes mellitus [30], and this class
of drugs has been clinically available for approximately
a decade. Some of the TZDs have been shown to exert
anti-inflammatory [31], antiproliferative [32], and antian-
giogenic effects [4]. The COX metabolite 15d-PGJ2 is a
natural PPARγ ligand and is considered a negative regulator
of inflammatory and immune responses [33]. More recent
results indicating that PPARγ activation may attenuate
inflammatory responses and cancer progression have led
to extensive investigation into the role of this protein in
inflammation and carcinogenesis.
PPARγ is expressed in human non-small-cell lung cancer
(NSCLC) and small cell lung carcinoma [34], and the expres-
sion of PPARγ has been correlated with tumor histological
type and grade [35]. In NSCLC, decreased PPARγ expression
was correlated with poor prognosis [3]. TZDs inhibit tumor
formation in a variety of animal models, including colon
[36] and lung cancers [37], and PPARγ over-expression
protects against tumor development in a mouse model of
lung tumorigenesis [38]. Further, increased PPARγ activity
promotes epithelial differentiation of NSCLC cells in 3D
culture [5]. It has also been shown that PPARγ inhibits the
growth of NSCLC in vitro and in vivo [5, 39, 40].
Cyclooxygenase is the rate-limiting enzyme for pro-
duction of prostaglandins and thromboxanes from free
arachidonic acid [41, 42]. Two COX isoforms, COX-1 and
COX-2, have been extensively studied. COX-1 is consti-
tutively expressed in most cells and tissues. COX-2 is an
inducible enzyme that acts to produce prostaglandins and/or
thromboxanes during an acute inflammatory response. The
direct enzymatic product of COX-2 and PGH2 is converted
to prostaglandins or thromboxanes by individual isomerases
or prostaglandin synthases, and relative production of the
various COX-2 products depends upon cellular concen-
trations of down-stream metabolic and catabolic enzymes
within the COX-2 pathway. In NSCLC, the major eicosanoid
produced is prostaglandin E2 (PGE2) through microsomal
PGE2 synthase (mPGES) activity. The nicotinamide ade-
nine dinucleotide positive-dependent catabolic enzyme 15-
hydroxyprostaglandin dehydrogenase (15-PGDH) metab-
olizes PGE2 to biologically inactive 15-keto derivatives.
The final PGE2 concentration experienced by NSCLC cells
depends upon expression of PGES and 15-PGDH. A large
body of evidence indicates that increased PGE2 produc-
tion contributes to tumorigenesis. COX-2 over-expression
is frequently observed in NSCLC, and the accompanying
increased proliferation, invasion, angiogenesis, and resis-
tance to apoptosis have been attributed in part to elevated
PGE2 production in the vicinity of the tumor. Thus, COX-
2 and its downstream signaling pathways represent potential
targets for lung cancer chemoprevention and therapy.
Studies indicate that COX-2 and PPARγ signaling path-
ways are intertwined. PPARγ ligands suppress COX-2 expres-
sion induced by LPS and PMA in macrophages, astrocytes,
and epithelial cells [43–45]. The COX-2 metabolite 15d-
PGJ2 is an endogenous ligand for PPARγ [46], and during
resolution of inflammation elevated 15d-PGJ2 production
downregulates COX-2 through a negative feedback loop
involving PPARγ and NF-κB [44, 47]. Synthetic and endoge-
nous PPARγ ligands decrease the high COX-2 expression
associated with several malignancies including cervical [48]
and liver cancers [49] and forced PPAR over-expression
decreases COX-2 levels in lung cancer cells [38]. While
PPARγ agonists decrease COX-2 expression or prevent COX-
2 induction in most settings, COX-2 expression is increased
in some studies [50, 51]. For example, Ikawa et al. reported
that rosiglitazone (also known as BRL49653) increases COX-
2 expression in human colorectal carcinoma cells [52].
PPARγ ligands also have been shown to induce COX-2
expression in mammary epithelial cells [53], monocytes [54],
and human synovial fibroblasts [55]. The effect of PPARγ
agonists on COX-2 expression may vary based upon the
cell type, the specific agonist molecule, and the presence
of additional inflammatory mediators. Off-target effects of
TZDs may also partially account for differences in the effects
of these molecules on COX-2 expression.
Although TZDs are widely known as ligands for PPARγ,
they may mediate receptor-independent effects, as previously
reported [56–58]. For example, by using embryonic stem
cells from PPARγ-null mice, Chawla et al. found that neither
macrophage differentiation nor anti-inflammatory effects of
synthetic PPARγ ligands are PPARγ receptor-dependent. To
distinguish the effects of PPARγ from off-target effects of
PPARγ ligands in lung cancer cells, Bren-Mattison et al.
utilized a molecular approach to over-express PPARγ in two
NSCLC cell lines and assessed the direct effect of PPARγ.
Their goal was to determine whether the antitumorigenic
effects of PPARγ were mediated via COX-2 pathways in
NSCLC. Their results clearly demonstrated that exogenously
expressed PPARγ suppresses COX-2 promoter activity and
protein expression resulting in suppression of PGE2 produc-
tion [38]. The COX-2 promoter has binding sites for cAMP
response element, NF-IL-6, and NF-κB [59]. Although the
COX-2 promoter contains multiple regulatory elements,
their data indicate that the inhibitory effects of PPARγ are
mediated through NF-κB. Several studies have demonstrated
that constitutive activation of NF-κB in tumor cells is
mediated through activation of Akt [60, 61]. Bren-Mattison
et al. demonstrated that the inhibitory effects of PPARγ
on COX-2 were mediated via increased activity of PTEN
leading to decreased phospho-Akt and inhibition of NF-κβ
[38]. These authors further demonstrated that transgenic
mice over-expressing PPARγ exhibited reduced COX-2 in
type II alveolar epithelial cells of lung, and those mice were
protected against lung cancer development in a chemical
carcinogenesis mouse model [38]. In summary, these data
indicate that COX-2 downregulation may mediate some of
the antitumorigenic effects of PPARγ over-expression.
The PPARγ agonists may also affect COX-2 in a PPARγ
independent manner (see Table 1). For example, in A549
NSCLC cells troglitazone enhanced both COX-2 and mPGES
expression in a concentration dependent manner, resulting
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Table 1: Off-target effects of TZDs in NSCLC.
Thiazolidinediones Molecular effects Mechanisms Reference
Troglitazone ↑ PGE2 ↑ COX-2, ERK and PI3K
phosphorylation
[62]
Pioglitazone, Rosiglitazone ↓ PGE2 ↑ 15-PGDH [14]
Ciglitazone ↓PGE2 ↓ COX-2 [13]
Phospholipid
Phospholiipase A
Arachidonic acid
PGG2
COX
COX
PGE synthase
PGH2
PGE2
15-PGDH
Biologically inactive keto derivative
Pioglitazone
Rosiglitazone
(both decrease PGE2)
Troglitazone
(increases PGE2)
Ciglitazone
(decreases PGE2)
(−)
(−)
(+)
(+)
(+)
(+)
Figure 1: Effects of various TZDs on the PGE2 pathway.
in a marked increase in PGE2 production [62]. Cotreatment
with the PPARγ antagonists GW9662 and bisphenol A digly-
cidyl ether (BADGE) had no effect on COX-2 induction by
troglitazone indicating that this event is PPARγ independent.
Troglitazone increased COX-2 expression at least in part
by activating ERK and PI3K pathways, which have been
previously demonstrated to influence COX-2 levels [63–65].
Combined troglitazone and TNFα stimulation resulted in
additive enhancement of COX-2 expression. The COX-2
metabolite 15d-PGJ2 had no detectable effects on COX-2 or
mPGES expression or PGE2 production in A549 cells. This
is consistent with the hypothesis that PPARγ-independent
mechanisms can partially account for discrepancies in the
effects of different TZD drugs on COX-2 expression. Thus,
in lung cancer, PPARγ agonists appear to regulate COX-2
expression and affiliated protumorigenic cellular phenotypes
through both PPARγ dependent and independent means.
We recently examined the effect of the pioglitazone and
rosiglitazone on COX-2 and PGE2 levels in A427 and A549
NSCLC cells. Both TZDs inhibited PGE2 production in
NSCLC cells via a COX-2 independent pathway. To define
the mechanism underlying COX-2 independent suppression
of PGE2 production, we focused on the prostaglandin
synthases that are responsible for the PGE2 production
and on 15PGDH the catabolic enzyme responsible for its
degradation to biologically inactive15-keto derivatives [66].
None of the three prostaglandin synthases (microsomal
PGES1, PGES2, and cytosolic PGES) was downregulated
by pioglitazone or rosiglitazone, however, 15-PGDH was
induced by TZDs. TZD-mediated suppression of PGE2
concentration was significantly inhibited by small interfering
RNA to 15-PGDH. Studies using dominant-negative PPARγ
over-expression or GW9662 revealed that the induction of
15-PGDH by both pioglitazone and rosiglitazone is PPARγ-
independent.These findings indicate that it is possible to use
a clinically available pharmacological intervention to sup-
press tumor-derived PGE2 by enhancing catabolism rather
than blocking synthesis. The potential benefits of inhibiting
PGE2 levels in a COX-2-independent manner include the
following. First, promoting 15-PGDH activity could decrease
PGE2 without modifying other prostaglandins such as PGI2.
This is potentially important because the latter has been
noted to have antitumor properties [67]. It has been
suggested that a ratio of PGs may be important in regulating
the malignant phenotype. Thus, inhibiting COX-2 activity
would diminish both PGE2 and PGI2, whereas selective
induction of 15-PGDH could lead to a more favorable
PGI2/PGE2 ratio. Second, suppression of PGE2 levels without
alteration in COX-2 may limit some of the cardiovascular
toxicities associated with COX-2 inhibition [68]. Finally,
unlike COX-2 inhibition, which may lead to upregulation of
certain leukotrienes that favor malignant progression [69],
15-PGDH induction may lead only to a decrement of PGE2.
This speculation will require further investigation.
Different TZDs have the capacity to modulate arachi-
donic acid metabolism by a variety of pathways (see
Figure 1). Recent evidence indicates that ciglitazone induces
differentiation and apoptosis in NSCLC [7]. The mech-
anisms of ciglitazone’s capacity to modulate PGE2 levels
in lung adenocarcinoma cells were recently reported [13].
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In contrast to pioglitazone and rosiglitazone, ciglitazone
mediates COX-2 dependent suppression of PGE2 in NSCLC.
Ciglitazone treatment suppressed COX-2 mRNA expression
and COX-2 promoter activity but did not modify the expres-
sion of enzymes downstream of COX-2 including PGES and
15-PGDH. Utilization of dominant-negative PPARγ showed
that suppression of COX-2 and PGE2 by ciglitazone is
mediated via non-PPAR pathways.
PPARγ ligands may also interfere with protumorigenic
signals derived from COX-2 by interrupting the function
of PGE2 G-protein coupled receptors (GPCRs) designated
E-prostanoid (EP) receptors 1–4 [70]. Han and Roman
found that in NSCLC cell lines, the PPARγ ligands GW1929,
15 dPGJ2, ciglitazone, troglitazone, and rosiglitazone signif-
icantly decreased EP2 mRNA and protein levels causing
growth inhibition in NSCLC cells [71]. The inhibitory effects
of rosiglitazone and ciglitazone but not 15d-PGJ2 were
suppressed by the PPARγ antagonist GW9662 suggesting
the involvement of PPARγ-dependent and independent
mechanisms.
Recently, a retrospective study by Govindarajan et al.
demonstrated a significant reduction in lung cancer risk
in diabetic patients using the TZD rosiglitazone [72].
Importantly, several clinical studies in diabetes patients have
demonstrated an increased risk of cardiovascular events asso-
ciated with rosiglitazone or pioglitazone treatment [73–75].
This is of particular significance in light of cardiovascular
toxicity associated with COX-2 inhibition. Recently, several
chemoprevention trials are being initiated using TZDs
[76]. However, adverse cardiac events are associated with
chronic TZD treatment [74]. Based on these findings, future
clinical studies attempting to utilize TZDs in prevention of
cancer will require selection of patient populations without
cardiovascular risk. Prospective clinical studies specifically
designed to address the effects of TZDs on cancer, and
cardiac outcomes are required. If the anti-inflammatory and
antitumor effects of TZDs are derived through pathways
distinct from those leading to cardiovascular toxicity, more
selective candidate drug molecules may be therapeuti-
cally effective, without leading to adverse cardiac events.
Thus, more research is required to define opportunities to
specifically interfere with PGE2 production, metabolism, or
downstream effects. This could ultimately lead to reduction
in lung cancer growth or prevention while leaving the steady-
state concentrations of desirable eicosanoids in tact [77].
Both elevated COX-2 and reduced PPARγ expression
are associated with poor prognosis in lung cancer patients
[3, 78–80] and recent work has revealed multiple interactions
between PPARγ signaling and the COX-2 pathway. The
COX-2 product 15d-PGJ2 is an endogenous ligand for
PPARγ, and PPARγ activation as a result of elevated 15d-
PGJ2 results in COX-2 downregulation in an autoregulatory
feedback loop that may contribute to natural resolution
of the inflammatory response [46]. Forced expression of
PPARγ decreases COX-2 expression in cultured human
NSCLC cells and mouse lungs and protects against lung
tumor development in a murine model [5, 38]. Synthetic
PPARγ ligands, several of which are currently approved for
treatment of diabetes, can interrupt several stages of the
COX-2/PGE2 protumorigenic pathway, although in certain
cases PPARγ ligands may increase COX-2 expression. These
effects are primarily mediated through PPARγ-independent
pathways (see Table 1). PPARγ ligands may directly decrease
COX-2 transcription in an NF-κB-dependent manner [38],
or they can interfere with downstream targets such as the
PGE2 receptor EP2 [71] or the enzyme responsible for
PGE2 catabolism, 15-PGDH [66]. The targets downstream
of COX-2 may be useful in light of recent evidence that
interfering with COX-2 enzymatic activity may increase risk
of cardiovascular events [68]. The discovery that certain
PPARγ agonists can specifically reduce PGE2 concentration
or expression of EP receptors may aid in the design of
strategies to reduce the effects of harmful prostaglandins
without impacting production of critical cardioprotective
eicosanoids.
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